DK1079856T3 - Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme - Google Patents

Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme

Info

Publication number
DK1079856T3
DK1079856T3 DK99924395T DK99924395T DK1079856T3 DK 1079856 T3 DK1079856 T3 DK 1079856T3 DK 99924395 T DK99924395 T DK 99924395T DK 99924395 T DK99924395 T DK 99924395T DK 1079856 T3 DK1079856 T3 DK 1079856T3
Authority
DK
Denmark
Prior art keywords
verotoxin
humanized antibodies
recognition
production
well
Prior art date
Application number
DK99924395T
Other languages
Danish (da)
English (en)
Inventor
Man Sung Co
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Maximiliano Vasques
Original Assignee
Teijin Ltd
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Pdl Biopharma Inc filed Critical Teijin Ltd
Application granted granted Critical
Publication of DK1079856T3 publication Critical patent/DK1079856T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99924395T 1998-05-20 1999-05-19 Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme DK1079856T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20

Publications (1)

Publication Number Publication Date
DK1079856T3 true DK1079856T3 (da) 2006-12-04

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924395T DK1079856T3 (da) 1998-05-20 1999-05-19 Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme

Country Status (20)

Country Link
US (1) US7846435B1 (ru)
EP (1) EP1079856B1 (ru)
JP (1) JP4044733B2 (ru)
KR (1) KR100548167B1 (ru)
CN (1) CN1330375C (ru)
AT (1) ATE335504T1 (ru)
AU (1) AU748852B2 (ru)
BR (1) BR9910589A (ru)
CA (1) CA2328485C (ru)
DE (1) DE69932719T2 (ru)
DK (1) DK1079856T3 (ru)
ES (1) ES2270598T3 (ru)
HK (1) HK1036215A1 (ru)
IL (2) IL139571A0 (ru)
NO (1) NO326197B1 (ru)
NZ (1) NZ508119A (ru)
PT (1) PT1079856E (ru)
RU (1) RU2217166C2 (ru)
WO (1) WO1999059629A1 (ru)
ZA (1) ZA200006370B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US8293245B2 (en) 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
RU2011126896A (ru) 2009-01-23 2013-02-27 Дзе Хенри М. Джексон Фаундейшн Фо Дзе Эдвенсмент Оф Милитэри Медисин, Инк. Композиция и полипептид для стимулирования иммунологической реакции на шига токсин 2 типа
CA2913702C (en) * 2013-05-27 2023-08-01 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
CA2132953C (en) 1992-03-26 2001-01-30 Howard C. Krivan Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
WO1996030043A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
NO20005833L (no) 2001-01-15
CA2328485C (en) 2011-05-03
HK1036215A1 (en) 2001-12-28
IL139571A (en) 2009-09-22
WO1999059629A1 (en) 1999-11-25
NO326197B1 (no) 2008-10-13
RU2217166C2 (ru) 2003-11-27
EP1079856A4 (en) 2002-03-13
PT1079856E (pt) 2006-12-29
AU748852B2 (en) 2002-06-13
NZ508119A (en) 2003-06-30
US7846435B1 (en) 2010-12-07
CA2328485A1 (en) 1999-11-25
EP1079856A1 (en) 2001-03-07
ZA200006370B (en) 2001-08-22
NO20005833D0 (no) 2000-11-17
DE69932719T2 (de) 2007-09-13
JP4044733B2 (ja) 2008-02-06
CN1330375C (zh) 2007-08-08
ES2270598T3 (es) 2007-04-01
KR100548167B1 (ko) 2006-01-31
ATE335504T1 (de) 2006-09-15
IL139571A0 (en) 2002-02-10
JP2002515230A (ja) 2002-05-28
EP1079856B1 (en) 2006-08-09
DE69932719D1 (de) 2006-09-21
BR9910589A (pt) 2001-01-16
CN1301175A (zh) 2001-06-27
KR20010052367A (ko) 2001-06-25
AU4090499A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
HK1044159A1 (zh) 抗γ-干擾素的人化抗體
RS80704A (en) ANTI- av?6.ANTIBODIES
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
MX2009006891A (es) Anticuerpos cd44.
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
DK1951759T3 (da) Anti-EGFR-antistoffer
MX2008007502A (es) Anticuerpos anti mn y metodos para su utilizacion.
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
MXPA05005925A (es) Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
SI1572087T1 (sl) Protitelesa proti antigenu tmeff2 raka in njihovauporaba
PT1214600E (pt) Determinacao de proteinas de ligacao a adrenomedulina
AU2002951409A0 (en) Methods for regulating cancer
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
DK1079856T3 (da) Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
WO2003049704A3 (en) Antibodies to treat cancer
WO2004053102A3 (en) Antibodies to treat cancer
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung